HRP20191511T1 - Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba - Google Patents

Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba Download PDF

Info

Publication number
HRP20191511T1
HRP20191511T1 HRP20191511T HRP20191511T1 HR P20191511 T1 HRP20191511 T1 HR P20191511T1 HR P20191511 T HRP20191511 T HR P20191511T HR P20191511 T1 HRP20191511 T1 HR P20191511T1
Authority
HR
Croatia
Prior art keywords
polypeptide
fusion protein
cdkl5
seq
use according
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of HRP20191511T1 publication Critical patent/HRP20191511T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HRP20191511 2014-02-28 2015-02-27 Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba HRP20191511T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP15736034.8A EP3110837B1 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (1)

Publication Number Publication Date
HRP20191511T1 true HRP20191511T1 (hr) 2019-11-29

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20191511 HRP20191511T1 (hr) 2014-02-28 2015-02-27 Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba
HRP20211324TT HRP20211324T1 (hr) 2014-02-28 2021-08-17 Tatk-cdkl5 fuzijski proteini, pripravci, formulacije, i njihova uporaba

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20211324TT HRP20211324T1 (hr) 2014-02-28 2021-08-17 Tatk-cdkl5 fuzijski proteini, pripravci, formulacije, i njihova uporaba

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2745335T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE055282T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3608334T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
CA3229127A1 (en) * 2021-08-18 2023-02-23 Julie Yu Wei Recombinant aav formulations
CN116874571A (zh) * 2021-12-17 2023-10-13 博格隆(上海)生物技术有限公司 突变的蛋白a结构域c及其应用
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609640A (en) * 2010-10-25 2015-06-26 Univ D’Aix Marseille Treatment of mecp2-associated disorders
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása

Also Published As

Publication number Publication date
IL247481A0 (en) 2016-11-30
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
IL275435A (en) 2020-08-31
EP3608334A1 (en) 2020-02-12
LT3110837T (lt) 2019-10-10
RS62244B1 (sr) 2021-09-30
ZA201606655B (en) 2020-05-27
US20160194617A1 (en) 2016-07-07
HUE045393T2 (hu) 2019-12-30
EA038000B1 (ru) 2021-06-22
US9290746B2 (en) 2016-03-22
DK3608334T3 (da) 2021-08-23
PH12016501689B1 (en) 2016-10-03
AU2015221860A1 (en) 2016-09-08
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
MX2016011167A (es) 2017-04-06
CR20160392A (es) 2017-06-12
US20180327725A1 (en) 2018-11-15
CA2940401C (en) 2022-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX392778B (es) 2025-03-24
JP2017507655A (ja) 2017-03-23
AU2015221860B2 (en) 2019-09-12
IL247481B (en) 2020-07-30
PL3110837T3 (pl) 2020-04-30
US10584318B2 (en) 2020-03-10
CY1124727T1 (el) 2022-07-22
CL2016002142A1 (es) 2017-09-08
JP6629747B2 (ja) 2020-01-15
KR102307276B1 (ko) 2021-09-30
SMT202100478T1 (it) 2021-09-14
US10907138B2 (en) 2021-02-02
HUE055282T2 (hu) 2021-11-29
EP3608334B1 (en) 2021-05-19
ES2745335T3 (es) 2020-02-28
DOP2016000220A (es) 2016-12-15
WO2015128746A3 (en) 2015-11-26
KR20170002372A (ko) 2017-01-06
WO2015128746A2 (en) 2015-09-03
AU2019219743B2 (en) 2020-10-29
SI3608334T1 (sl) 2021-11-30
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
EP3110837B1 (en) 2019-06-12
SG11201606863YA (en) 2016-09-29
US20200199549A1 (en) 2020-06-25
JP6896050B2 (ja) 2021-06-30
PT3110837T (pt) 2019-09-12
SG10202000537RA (en) 2020-03-30
SI3110837T1 (sl) 2019-12-31
NI201600127A (es) 2017-03-13
EP3110837A2 (en) 2017-01-04
NZ723371A (en) 2023-11-24
EA201691691A1 (ru) 2017-05-31
SV2016005264A (es) 2017-02-15
SMT201900504T1 (it) 2019-11-13
PT3608334T (pt) 2021-08-25
BR112016019868A2 (pt) 2017-10-17
JP2020062022A (ja) 2020-04-23
PL3608334T3 (pl) 2021-11-22
PH12016501689A1 (en) 2016-10-03
PE20161406A1 (es) 2017-01-14
ES2885245T3 (es) 2021-12-13
BR112016019868B1 (pt) 2023-11-28
HRP20211324T1 (hr) 2021-11-26
MX2020001223A (es) 2022-05-31
CA2940401A1 (en) 2015-09-03
RS59344B1 (sr) 2019-10-31
US9944910B2 (en) 2018-04-17
EA202190727A2 (ru) 2021-07-30
AU2019219743A1 (en) 2019-09-19
US20150247134A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
HRP20210734T1 (hr) Koštani morfogenetski proteini
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2013172734A5 (enExample)
DK3915553T3 (da) Sammensætninger indeholdende aminosyrer til brug i behandlingen af mitokondrie-dysfunktion-relaterede neurodegenerative sygdomme
MX388977B (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
EA201990848A1 (ru) ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B
MX395266B (es) Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis.
PL3865506T3 (pl) Białko fuzyjne do zastosowania w leczeniu choroby hvg
EP3354664A4 (en) PROTEIN CONJUGATE WITH SEVERAL BIOACTIVE POLYPEPTIDES AND IMMUNOGLOBULIN FC REGIONS
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
EP3278810A4 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
MX384236B (es) Productos farmaceuticos mejorados de peptido para resistencia a la insulina
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2024012898A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
EP3643723C0 (en) NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES COMPRISING SAID NOVEL PEPTIDE AS ACTIVE INGREDIENT
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
IL269187B1 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
WO2019195714A8 (en) Methods and compositions for treating skin disease with recombinant microorganisms
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
EP3530278A4 (en) COMPOSITION WITH PROTEIN-PHOSPHATASE-1-INHIBITING PEPTIDE FOR THE TREATMENT OF VASCULAR DISEASES
WO2016011201A3 (en) Epha4 cyclic peptide antagonists for neuroprotection and neural repair